Caffeoyl pyrrolidine derivative LY52 inhibits hepatocellular carcinoma invasion via suppressing matrix metalloproteinase-2

[1]  F. Qi,et al.  Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. , 2008, Drug discoveries & therapeutics.

[2]  N. Kokudo,et al.  Effect of benzyl-N-acetyl-α-galactosaminide on KL-6 mucin expression and invasive properties of a human pancreatic carcinoma cell line. , 2008, Drug discoveries & therapeutics.

[3]  T. Pawlik,et al.  Biology of Hepatocellular Carcinoma , 2008, Annals of Surgical Oncology.

[4]  Lianyue Yang,et al.  The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases , 2007, International journal of cancer.

[5]  M. Makuuchi,et al.  Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumor invasion and metastasis. , 2006, International journal of molecular medicine.

[6]  C. Bréchot,et al.  Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis , 2006, Oncogene.

[7]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[8]  Wenfang Xu,et al.  Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. , 2006, Bioorganic & medicinal chemistry.

[9]  Christian Bréchot,et al.  Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. , 2004, Gastroenterology.

[10]  Cheorl-Ho Kim,et al.  Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. , 2004, The international journal of biochemistry & cell biology.

[11]  Wenfang Xu,et al.  Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. , 2004, Bioorganic & medicinal chemistry.

[12]  A. Albini,et al.  New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2). , 2004, Bioorganic & medicinal chemistry.

[13]  Tae-Wook Chung,et al.  Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. , 2002, Archives of biochemistry and biophysics.

[14]  Ding-Shinn Chen,et al.  Global control of hepatitis B virus infection. , 2002, The Lancet. Infectious diseases.

[15]  A. Henney,et al.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.

[16]  A. Harris,et al.  Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Boudjema,et al.  Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas , 2001, Hepatology.

[18]  M. Makuuchi,et al.  Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. , 2000, International journal of oncology.

[19]  Y. Soini,et al.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  C. Bréchot,et al.  Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). , 2000, Seminars in cancer biology.

[21]  H. Tsuzuki,et al.  Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. , 1999, Journal of medicinal chemistry.

[22]  H. Yamamoto,et al.  Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. , 1997, Gastroenterology.

[23]  M. Shapiro,et al.  Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Twelves,et al.  A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid , 2004, Cancer Chemotherapy and Pharmacology.

[26]  J. Bruix,et al.  Hepatitis B virus and hepatocellular carcinoma. , 2003, Journal of hepatology.